Loop-Controlled Precision Pulse | Successful Live Demonstration of AccuPulse Adjustable-Loop PFA System at CHRS 2026 at The Fourth Affiliated Hospital of Soochow University

SUZHOU, China—AccuPulse Medical Technology Co. Ltd., a Chinese medical-device company focused on cardiac electrophysiology, marked a significant milestone as its pulsed field ablation (PFA) system was successfully deployed in a live clinical demonstration during the 26th Congress of Heart Rhythm Society (CHRS 2026).

The procedure, performed at The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), showcased the AccuPulse disposable cardiac PFA catheter and AccuBlator cardiac PFA generator in treating a patient with atrial fibrillation—a common heart rhythm disorder that affects millions worldwide.

Led by Dr. Wang Linlin, director of the cardiology department, the medical team completed a pulmonary vein isolation (PVI) procedure on a 70-year-old male patient with a left atrial diameter of 47 millimeters. The surgeons utilized the AccuPulse 20-25mm adjustable-loop catheter, a device designed to adapt to varying pulmonary vein anatomies.

A Streamlined Procedure

The procedure demonstrated remarkable efficiency. From venous puncture to transseptal puncture completion took just five minutes, while mapping and modeling required nine minutes. Total dwell time in the left atrium was 91 minutes.

Across all four pulmonary veins, the system delivered 189 ablation pulses with a cumulative energy delivery time of 33.075 seconds. The breakdown by vein was as follows: the left superior pulmonary vein received 42 pulses (24 at the ostium, 18 at the antrum); the left inferior pulmonary vein received 57 pulses (30 at the ostium, 27 at the antrum); the right superior pulmonary vein received 36 pulses (30 at the ostium, 6 at the antrum); and the right inferior pulmonary vein received 54 pulses (24 at the ostium, 30 at the antrum).

Notably, during ablation of the left superior pulmonary vein, the patient's atrial fibrillation spontaneously converted to normal sinus rhythm—a positive clinical indicator. Post-ablation substrate mapping confirmed good left atrial tissue characteristics with satisfactory isolation of all four pulmonary veins and their antra.

Technology With 'Three Core Advantages'

The AccuPulse system differentiates itself through three core advantages: integrated mapping and modeling with a single-loop catheter, efficient ablation delivery, and a strong safety profile.

The device features a proprietary 7.5 French adjustable-loop design that allows physicians to select between 15-20mm or 20-25mm loop diameters, enabling personalized adaptation to each patient's unique pulmonary vein anatomy. The system also incorporates AccuPulse's self-developed impedance-based contact feedback technology, which provides real-time monitoring of catheter-tissue contact quality.

Perhaps most significantly, the loop catheter integrates mapping, modeling, and ablation functions into a single device. This consolidation reduces reliance on additional high-density mapping catheters traditionally required during such procedures, potentially lowering both procedural complexity and consumable costs.

Clinical Validation and Expert Assessment

In their post-procedure assessment, the clinical team noted that the adjustable-loop PFA catheter performed excellently during both the modeling and mapping phases. The catheter achieved precise modeling, successfully enabling three-dimensional reconstruction of the left atrium and pulmonary vein structures. Substrate mapping results were favorable, providing clear and reliable navigation support throughout the procedure.

"The entire catheter manipulation process was smooth, and the operator experience was satisfactory," the team reported. They highlighted that the catheter achieved efficient pulmonary vein isolation with a total of 189 energy deliveries completing ablation of both the ostia and antra of all four pulmonary veins, with flexible and controllable discharge strategies reflecting sound engineering design.

Overall, the team concluded that the ablation system is "safe, controllable, and excellent in modeling"—representing a reliable tool for pulsed field ablation in atrial fibrillation treatment.

A Milestone for Domestic PFA Technology

The successful clinical application marks the formal entry of this innovative domestic PFA system into clinical practice, offering what AccuPulse describes as a superior option for atrial fibrillation interventional treatment.

The Fourth Affiliated Hospital of Soochow University's cardiovascular department is well-positioned to advance this technology. Designated as a Jiangsu Provincial Clinical Key Specialty and home to multiple national centers—including a Chinese Chest Pain Center, Chinese Heart Failure Center, and Chinese Atrial Fibrillation Center—the institution brings substantial clinical infrastructure to the collaboration.

Looking ahead, AccuPulse plans to deepen clinical cooperation with the hospital to advance standardized application and promotion of PFA technology, with the goal of providing internationally leading, one-stop atrial fibrillation diagnosis and treatment solutions for arrhythmia patients across China.

The pulsed field ablation approach represents a broader shift in cardiac electrophysiology toward non-thermal energy sources that can destroy problematic tissue while potentially sparing surrounding structures—a development that could reshape treatment paradigms for atrial fibrillation patients globally.